Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.

Although the onset of irAEs was difficult to be predicted based on pre-treatment tests. It appeared that the continuation of ICI therapy, along with early detection and adequate control of irAEs, might contribute to the improved prognosis of patients.